|
Survival rates in the subgroups of the study population |
|||
| Death |
|||
|
|
|||
| Subgroups |
n |
Survival (%) |
p |
|
|
|||
| Demographic characteristics |
|||
| Males/Females |
779/184 |
94.5/93.3 |
0.473 |
| Age ≥ 65/< 65 years |
516/447 |
92.1/96.7 |
0.002 |
| Medical history |
|||
| Hypertension yes/no |
405/558 |
94.3/94.2 |
0.927 |
| Diabetes mellitus yes/no |
123/840 |
94.1/94.3 |
0.939 |
| Hypercholesterolemia yes/no |
465/498 |
95.8/92.8 |
0.069 |
| Past or current smoking yes/no |
491/472 |
95.3/93.2 |
0.152 |
| BMI ≥ 25/< 25 (kg/m2) |
619/344 |
95.0/93.3 |
0.246 |
| Family history of MI yes/no |
272/691 |
95.8/93.6 |
0.209 |
| Prior MI yes/no |
297/666 |
95.9/93.5 |
0.179 |
| Prior PCI yes/no |
128/835 |
96.0/94.0 |
0.396 |
| Prior CABG yes/no |
89/874 |
91.9/94.5 |
0.323 |
| GP III a polymorphism |
|||
| A1A1/A1A2/A2A2 |
690/248/25 |
95.0/91.8/100.0 |
0.076 |
| PCI indication |
|||
| Stable angina |
152 |
97.3 |
0.572 |
| Unstable angina |
365 |
94.3 |
|
| MI |
282 |
94.1 |
|
| Post MI |
117 |
92.7 |
|
| Other |
47 |
93.0 |
|
| Coronary artery vessels diseased |
|||
| Single+two-/three-vessel disease |
746/217 |
94.9/92.1 |
0.185 |
| LVEF ≥ 40%/< 40% |
808/155 |
95.0/90.5 |
0.022 |
| Therapy |
|||
| ACE inhibitor yes/no |
316/647 |
94.4/94.1 |
0.886 |
| Beta-blocker yes/no |
546/417 |
96.0/92.0 |
0.011 |
| Statin yes/no |
334/629 |
95.9/93.3 |
0.114 |
| Revascularisation during follow-up |
|||
| PCI yes/no |
145/818 |
99.3/93.4 |
0.008 |
| CABG yes/no |
29/934 |
86.1/94.5 |
0.047 |
| Therapy during follow-up |
|||
| Statin yes/no |
462/501 |
96.2/92.5 |
0.017 |
| ACE inhibitor yes/no |
338/625 |
100.0/91.1 |
< 0.001 |
| Beta-blocker yes/no |
580/383 |
99.8/85.8 |
< 0.001 |
|
ACE, angiotensin converting enzyme; BMI, body mass index; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention. | |||
Le Hello et al. Thrombosis Journal 2007 5:19 doi:10.1186/1477-9560-5-19 |
|||